In The News

05/16/2017
Acute respiratory disease (ARD) due to infection with adenovirus is a major cause of morbidity at military training centers. In addition to ARD, adenovirus infection can cause sore throat, pneumonia, conjunctivitis, and urinary infections. Military...
The Hill - 10/31/2016
Two years ago, Americans and Europeans watched in collective horror as a faceless, indiscriminate killer landed in their midst without warning. Fear and widespread anxiety were joined by deep frustration at the apparent unpreparedness to handle a...
Associated Press - 06/10/2016
WASHINGTON — Federal health officials have approved the first cholera vaccine intended to protect U.S. travelers from the potentially life-threatening disease. The Food and Drug Administration approved the liquid vaccine, called Vaxchora, for adults...
05/17/2016
As mosquito season kicks into high gear and the threat of Zika transmission in the United States grows, the global health community is grappling with how to address not only the potential for large-scale outbreaks in the near-term but the...
Pharmaceutical Executive - 03/04/2016
Another biotech firm with a California startup address that thinks it can leverage its expertise is Redwood City-headquartered PaxVax. “Along with many others, PaxVax is now in the early stages for developing a Zika vaccine,” according to CEO Nima...
FierceVaccines - 02/10/2016
PaxVax plans to bring its candidate to animal trials during the first half of this year, CEO Nima Farzan told FierceVaccines. Farzan said, governments and nongovernmental organizations like the WHO should create economic incentives for companies to...
Fox 5 TV - 02/09/2016
Scientist Jonathan Smith says PaxVax already has developed a vaccine for typhoid and is in the final stages of bringing a cholera vaccine to market. He said little is known about Zika, but a lot of what scientists think they know, they are...
San Diego Union Tribune - 02/07/2016
PaxVax develops vaccines for infectious diseases in what the privately held company calls a "socially responsible' manner. It reports having raised more than $200 million from investors. This includes $105 million in December from Cerberus Capital...
FierceVaccines - 12/16/2015
Just a week after announcing a $105 million investment by Cerberus Capital, PaxVax is inching closer to getting its second vaccine--and potentially the first FDA-approved cholera vaccine--to market. The Redwood City, CA-based company announced...
FierceVaccines - 12/09/2015
Redwood City, CA-based PaxVax currently markets one vaccine, Vivotif, the typhoid vaccine it acquired from Johnson & Johnson's ($JNJ) Crucell in July 2014. But PaxVax could be on the way to adding its cholera candidate, Vaxchora, to the list...

Pages